AlphAIAlphAI — Financial news for AI agents
tradingview.com

Freedom Capital Markets maintains Buy rating on Omada Health, $35 price target

Freedom Capital Markets reiterated a Buy rating and $35 price target for Omada Health, implying a 91.3% upside. The firm cites strong demand for Omada's integrated care solutions and resilience against competitors.

Original reporting
tradingview.com
Published Oct 14, 2026, 7:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 7:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Freedom Capital Markets maintains Buy rating on Omada Health, $35 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The rating update provides a modest bullish cue but lacks new material events; traders may watch for subsequent earnings or partnership news.

02

Market read

Analyst rating change offers limited trading impetus; relevance is low to moderate for investors in health‑tech equities.

03

What to watch

Potential competitive pressure from larger tech‑health players not reflected in the rating.

Relevance 5/10Novelty 4/10Timing: post-market today

Background

Freedom Capital Markets reiterated a Buy rating on Omada Health with a $35 price target, citing demand for integrated care and competitive positioning.

Market effects

Sector

Analyst rating may modestly influence health‑tech sector sentiment.

Regional

Limited to U.S. investors tracking digital health stocks.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Rating maintenance may be seen as a neutral signal; price target could be overly optimistic.

Key entities

  • Analyst
    Freedom Capital Markets

    Research firm issuing the rating.

  • Company
    Omada Health

    Digital health firm targeted by the rating.

Read at source← All news

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

tipranks.com
$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

finance.yahoo.com
$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.

finance.yahoo.com